Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac N.V. Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

11/18/2021 | 05:42am EST

CureVac N.V. announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12-g of CV2CoV or a 30-g standard dose of Comirnaty(R) were shown to be highly comparable. The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach. This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole. The study, conducted in collaboration with Dan Barouch, MD, PhD, of Beth Israel Deaconess Medical Center, investigated immune responses as well as the protective efficacy of CV2CoV and first-generation candidate, CVnCoV, against SARS-CoV-2 challenge in cynomolgus macaques. It was made available via the bioRxiv preprint server in August 2021. For additional details, please refer to the previously issued press release. About the Study: Within the study, CV2CoV and CVnCoV were tested in cynomolgus macaques immunized with a 12-g dose of the respective candidate on day 0 and day 28. For comparison with Comirnaty(R), animals were vaccinated twice, on day 0 and day 21, with 30-g of the licensed vaccine and antibody titers were measured at peak immunity at week 5. Within the comparison of CV2CoV with CVnCoV, CV2CoV consistently showed better activation of innate and adaptive immune responses, resulting in earlier response onset, higher antibody titers and stronger memory B and T cell activation. Higher antibody neutralizing capacity was observed with CV2CoV across a range of relevant variants, including the Delta variant. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected than animals vaccinated with CVnCoV based on effective clearance of the virus in the lungs and nasal passages.

© S&P Capital IQ 2021
All news about CUREVAC N.V.
01/13CUREVAC N : In relation to the Parties' share portfolios in CureVac N.V. (NL-Amsterdam) - ..
01/03CUREVAC N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as..
2021CureVac Stock Slips Following Kempen's Stock Rating Downgrade
2021Kempen Downgrades CureVac to Sell From Neutral, Adjusts Price Target to $20 From $50
2021CUREVAC N.V.(NASDAQGM : CVAC) added to NASDAQ Biotechnology Index
2021CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
2021CureVac N.V. Reports Earnings Results for the Nine Months Ended September 30, 2021
2021Berenberg Bank Adjusts CureVac's Price Target to $70 From $123, Maintains Buy Rating
2021UK study finds mRNA COVID-19 vaccines provide biggest booster impact
2021GSK names Pfizer scientist Dormitzer as vaccines R&D head
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Sales 2021 - - -
Net income 2021 -428 M -488 M -488 M
Net cash 2021 976 M 1 114 M 1 114 M
P/E ratio 2021 -9,13x
Yield 2021 -
Capitalization 6 719 M 7 669 M 7 671 M
EV / Sales 2021 -
EV / Sales 2022 19,8x
Nbr of Employees 505
Free-Float 45,1%
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 21,45 €
Average target price 44,43 €
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-28.65%7 669
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068